Antiviral Research

Article	Citations
Metformin inhibits EV-A71 and CVA16 infections by regulating TRIB3-SCARB2 axis and activating AMPK	352
M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings	97
25R,26-hydroxycholesterol and an oxysterol synthetic analog inhibit Varicella zoster Virus replication	90
Editorial Board	75
Development of nebulized inhalation delivery for fusion-inhibitory lipopeptides to protect non-human primates against Nipah-Bangladesh infection	58
Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy	58
Seeking innovative concepts in development of antiviral drug combinations	57
Generation and characterization of mouse monoclonal antibodies against the VP4 protein of group A human rotaviruses	55
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	53
Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model	52
Importin α/β-dependent nuclear transport of human parvovirus B19 nonstructural protein 1 is essential for viral replication	52
A proof-of-concept study for the efficacy of dispirotripiperazine PDSTP in a rabbit model of herpes simplex epithelial keratitis	51
Caffeic acid phenethyl ester: an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus	49
Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment	45
Increased ILT2 expression contributes to dysfunction of CD56dimCD16+NK cells in chronic hepatitis B virus infection	43
Editorial Board	42
Editorial Board	39
Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model	38
A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission	38
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants	34
Editorial Board	33
New therapeutic perspective in the prevention of congenital cytomegalovirus infection	33
Editorial Board	33
Paxlovid for hospitalized COVID-19 patients with chronic kidney disease	33
Meeting report: 36th International Conference on Antiviral Research in Lyon, France – March 13–17, 2023	31

Ceragenins exhibit antiviral activity against SARS-CoV-2 by increasing the expression and release of type I interferons upon activation of the host's immune response	31
Advanced virtual screening enables the discovery of a host-targeting and broad-spectrum antiviral agent	31
Abemaciclib restricts HCMV replication by suppressing pUL97-mediated phosphorylation of SAMHD1	30
Editorial Board	29
Interferon α facilitates anti-HBV cellular immune response in a B cell-dependent manner	29
Broad-spectrum antiviral diazadispiroalkane core molecules block attachment and cell-to-cell spread of herpesviruses	29
Editorial Board	28
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	28
Editorial Board	26
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	25
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	25
Editorial Board	25
A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy	25
Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors	24
PRO-2000 exhibits SARS-CoV-2 antiviral activity by interfering with spike-heparin binding	23
Identification of a macrocyclic compound targeting the lassa virus polymerase	23
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	23
Editorial Board	22
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge	22
Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro	22
X-206 exhibits broad-spectrum anti-β-coronavirus activity, covering SARS-CoV-2 variants and drug-resistant isolates	21
Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20–24, 2024, organized by the International Society for Antiviral Research	21
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells	21
Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD	21
Importin KPNA2 confers HIV-1 pre-integration complex nuclear import by interacting with the capsid protein	21
Induction of antiviral gene expression by cyclosporine A, but not inhibition of cyclophilin A or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line	21
Liver biopsy of chronic hepatitis B patients indicates HBV integration profile may complicate the endpoint and effect of entecavir treatment	20
Filociclovir is a potent inhibitor of human adenovirus F41	20
Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytes	20
Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2	20
Anti-influenza virus activity of the REV-ERBα agonist SR9009 and related analogues	20
Novel reverse genetics of genotype I and III Japanese encephalitis viruses assembled through transformation associated recombination in yeast: The reporter viruses expressing a green fluorescent prote	20
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	20
Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action	20
Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy	19
Thioxothiazolo[3,4-a]quinazoline derivatives inhibit the human cytomegalovirus alkaline nuclease	19
Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications	19
Locked-nucleotide antagonists to varicella zoster virus small non-coding RNA block viral growth and have potential as an anti-viral therapy	19
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	18
Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants	18
Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay	18
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance	18
Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus	18
A lipid index for risk of hyperlipidemia caused by anti-retroviral drugs	18
Host-targeting antivirals for chronic viral infections of the liver	18
Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection	18
Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry	17
Optimal flexibility of the linker region of Zika virus NS5 methyltransferase-polymerase is critical for virus replication	17
Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease	17
A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency	16

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CLpro	16
Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo	16
Optimization of Bangladesh and Malaysian genotype recombinant reporter Nipah viruses for in vitro antiviral screening and in vivo disease modeling	16
Interferon-induced restriction of Chikungunya virus infection	16
Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404	16
A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2	16
Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus	16
Characterization of an air-liquid interface primary human vaginal epithelium to study Ebola virus infection and testing of antivirals	15
CD47 expression attenuates Ebola virus-induced immunopathology in mice	15
A novel phthalazinone derivative as a capsid assembly modulator inhibits hepatitis B virus expression	15
Severe mammarenaviral disease in guinea pigs effectively treated by an orally bioavailable fusion inhibitor, alone or in combination with favipiravir	15
PZR suppresses innate immune response to RNA viral infection by inhibiting MAVS activation in interferon signaling mediated by RIG-I and MDA5	15
Identification of a novel acylthiourea-based potent broad-spectrum inhibitor for enterovirus 3D polymerase in vitro and in vivo	15
Antiviral effect of peptoids on hepatitis B virus infection in cell culture	15
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	14
Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication	14
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants	14
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	14
Targeting SARS-CoV-2 and host cell receptor interactions	14
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines	14
Editorial Board	14
Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus	13
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors	13
Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.	13
Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins	13
Sangivamycin is preferentially incorporated into viral RNA by the SARS-CoV-2 polymerase	13
E3 ubiquitin ligase TRIM21 restricts hepatitis B virus replication by targeting HBx for proteasomal degradation	13
Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels	13
Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action	13
A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection	13
Corrigendum to “Discovery of ZFD-10 of a pyridazino[4,5-b]indol-4(5H)-one derivative as an anti-ZIKV agent and a ZIKV NS5 RdRp inhibitor” [Antivir. Res. 214 (2023) 105607]	13
Influenza antivirals and their role in pandemic preparedness	13
Glucocorticoid receptor and specificity protein 1 (Sp1) or Sp3, but not the antibiotic Mithramycin A, stimulates human alphaherpesvirus 1 (HSV-1) replication	13
Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein	13
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	13
Mouse models of Zika virus transplacental transmission	12
In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2	12
Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice	12
Dengue Virus dependence on glucokinase activity and glycolysis Confers Sensitivity to NAD(H) biosynthesis inhibitors	12
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial	12
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern	12
Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model	12
Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target	12
CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation	12
Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system	12
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	12
Inhibition of influenza A virus proliferation in mice via universal RNA interference	12
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020	12
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	12
Breaking the mold: Overcoming resistance to immune checkpoint inhibitors	11
Editorial Board	11
Conserved use of the sodium/bile acid cotransporter (NTCP) as an entry receptor by hepatitis B virus and domestic cat hepadnavirus	11
Editorial Board	11
Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp	11
Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection	11
An antibody engineering platform using amino acid networks: A case study in development of antiviral therapeutics	11
Monoglycosylated SARS-CoV-2 receptor binding domain fused with HAstem-scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses	11
Tarsal exposure to atovaquone inhibits chikungunya virus transmission by Aedes aegypti mosquitoes, but not the transmission of Zika virus	11
Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza A viruses with M2S31N-based drug resistance	11
An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge	11
The life cycle of the alphaviruses: From an antiviral perspective	11
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow!	11
Quindoline-derivatives display potent G-quadruplex-mediated antiviral activity against herpes simplex virus 1	10
The calcium channel inhibitor lacidipine inhibits Zika virus replication in neural progenitor cells	10
Editorial Board	10
Corrigendum to “The novel therapeutic target and inhibitory effects of PF-429242 against Zika virus infection” [Antivir. Res. vol 192 (2021) 1–13/105121]	10
Editorial Board	10
Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus	10
Corrigendum to “Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts” [Anti. Res. 179 (2020) 104818]	10
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	10
Inhibitors of mpox VP39 2′-O methyltransferase efficiently inhibit the monkeypox virus	10
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	10
Editorial Board	10
Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method	10
Corrigendum to “The race toward a universal influenza vaccine: Front runners and the future directions” [Antivir. Res. (2022) 105505]	10
Editorial Board	10
Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants	10
Inhibitory effect of a novel thiazolidinedione derivative on hepatitis B virus entry	10
Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes	10
Shikonin, an inhibitor of inflammasomes, inhibits Epstein-Barr virus reactivation	10

Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022–2023 season	9
Licochalcone A inhibits enterovirus A71 replication in vitro and in vivo	9
Activation of cGAS-STING suppresses coxsackievirus replication via interferon-dependent signaling	9
In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimean–Congo hemorrhagic fever virus	9
Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection	9
Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients	9
Phenotypic and genotypic acyclovir resistance surveillance of genital herpes simplex virus 2 in South Africa	9
Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection	9
Structural and quantitative comparison of viral infection-associated N-glycans in plasma from humans, pigs, and chickens: Greater similarity between humans and chickens than pigs	9
Inhibition of endocytosis of porcine reproductive and respiratory syndrome virus by rottlerin and its potential prophylactic administration in piglets	9
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids	9
Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792	9
Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2	9
Editorial Board	9
Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus	9
Preclinical animal models to evaluate therapeutic antiviral antibodies	9
Potency of a small molecule that targets the molluscum contagiosum virus processivity factor increases when conjugated to a tripeptide	9
Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine	9
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses	9
Development and optimization of biologically contained Marburg virus for high-throughput antiviral screening	9
Lectibodies as antivirals	9
Association of C-reactive protein polymorphisms with serum-CRP concentration and viral load among dengue-chikungunya mono/co-infected patients	9
A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies	9
Dynamic features of virus protein 1 and substitutions in the 3-phenyl ring determine the potency and broad-spectrum activity of capsid-binding pyrazolo[3,4-d]pyrimidines against rhinoviruses	9
DDX20 positively regulates the interferon pathway to inhibit viral infection	8
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate	8
Double synergic chitosan-coated poly (lactic-co-glycolic) acid nanospheres loaded with nucleic acids as an intranasally administered vaccine delivery system to control the infection of foot-and-mouth	8
Topoisomerase 3b is dispensable for replication of a positive-sense RNA virus--murine coronavirus	8
SiRNAs as antiviral drugs – Current status, therapeutic potential and challenges	8
A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines	8
Promises and challenges of single-domain antibodies to control influenza	8
Targeting the alphavirus virus replication process for antiviral development	8
Discovery of a small-molecule inhibitor of KSHV lytic replication from the MMV pandemic response box	8
Identification of broad-spectrum neutralizing antibodies against influenza A virus and evaluation of their prophylactic efficacy in mice	8
Synthesis and virucide activity on zika virus of 1,2,3-triazole-containing vanillin derivatives	8
Pellino-1, a therapeutic target for control of SARS-CoV-2 infection and disease severity	8
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters	8
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study	8
Evaluating Z-FA-FMK, a host cathepsin L protease inhibitor, as a potent and broad-spectrum antiviral therapy against SARS-CoV-2 and related coronaviruses	8
Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy	8
New directions in the experimental therapy of tick-borne encephalitis	8
Orally dissolving film as a potential vaccine delivery carrier to prevent influenza virus infection	8
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection	8
MicroRNA-124 expression in Kupffer cells modulates liver injury by targeting IL-6/STAT3 signaling	8
In vitro evaluation of tropolone absorption, metabolism, and clearance	8
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model	8
Corrigendum to “Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics” “Antiviral Research 209 (2023)/105484”	8
Recombinant pseudorabies virus (PRV) expressing stabilized E2 of classical swine fever virus (CSFV) protects against both PRV and CSFV	8
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection	8
Anti-HBc mirrors the activation of HBV-specific CD8+ T cell immune response and exhibits a direct effect on HBV control	7
Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster mod	7
The hepatic GABAergic system promotes liver macrophage M2 polarization and mediates HBV replication in mice	7
Hijacking JAKis: JAK inhibitors as potential antiviral molecules, a mini review	7
Anisomycin inhibits Coxsackievirus B replication by promoting the lysosomal degradation of eEF1A1	7
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors	7
Pilot-scale production of inactivated monoglycosylated split H1N1 influenza virus vaccine provides cross-strain protection against influenza viruses	7
Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir	7
Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies	7
Tissue replication and mucosal swab detection of Sosuga virus in Syrian hamsters in the absence of overt tissue pathology and clinical disease	7
Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	7
β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus	7
Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants	7
The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer	7
Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription	7
Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains	7
Inhibition of HBV replication by EVA1A via enhancing cellular degradation of HBV components and its potential therapeutic application	7
Broadly neutralizing antibodies to combat influenza virus infection	7
Posaconazole inhibits multiple steps of the alphavirus replication cycle	7
HBV Core-specific CD4+ T cells correlate with sustained viral control upon off-treatment in HBeAg-positive chronic hepatitis B patients	7
Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides	7
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine	7
SRPKIN-1 as an inhibitor against hepatitis B virus blocking the viral particle formation and the early step of the viral infection	7
Synergistic activity of an RNA polymerase PA-PB1 interaction inhibitor with oseltamivir against human and avian influenza viruses in cell culture and in ovo	7
Effect of E23G/K, F36V, N37T, E119D, and E199G polymerase acidic protein substitutions on the replication and baloxavir susceptibility of influenza B viruses	7
Putative targeting by BX795 causes decrease in protein kinase C protein levels and inhibition of HSV1 infection	7
Efficient rescue of a newly classified Ebinur lake orthobunyavirus with GFP reporter and its application in rapid antiviral screening	7
IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility	7
RBM24 inhibits the translation of SARS-CoV-2 polyproteins by targeting the 5ʹ-untranslated region	7
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome	7
Erratum to “BX795 demonstrates potent antiviral benefits against herpes simplex Virus-1 infection of human cell lines” [Antivir. Res. 80 (2020) 104814]	7
Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019–2020 season in Japan and detection of influenza virus with the PA E23K substitution	7
Mouse models of Ebola virus tolerance and lethality: characterization of CD-1 mice infected with wild-type, guinea pig-adapted, or mouse-adapted virus	7
Sulforaphane suppresses dengue virus replication by inhibition of dengue protease and enhancement of antiviral interferon response through Nrf2-mediated heme oxygenase-1 induction	7
Naturally occurring pre-S mutations promote occult HBV infection by affecting pre-S2/S promoter activity	7
Editorial Board	6
Editorial Board	6
Mosaic neuraminidase-based vaccine induces antigen-specific T cell responses against homologous and heterologous influenza viruses	6
Editorial Board	6
Evaluation of a novel severe combined immunodeficiency mouse model for antiviral drug evaluation against Chandipura virus infection	6
Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies	6
Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment	6
75 years of bovine viral diarrhea virus: Current status and future applications of the use of directed antivirals	6
Lipid phosphatase SAC1 suppresses hepatitis B virus replication through promoting autophagic degradation of virions	6
An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity	6
A molecular perspective for the development of antibodies against the human respiratory syncytial virus	6